Thermo Fisher: Immuno-Oncology Biomarker Discovery

November 14, 2018

Share :

LabCentral 700

Location: Lobby
Time: 11:00 AM - 1:00 PM


11:00AM  - 11:45 AM
Emerging biomarkers for immunotherapy: from tumor mutational burden (TMB) to gene expression profiling

  • Jin Li, Ph.D – Executive Scientific Director of Advanced Diagnostics, MolecularMD, Cambridge MA

Use of immune checkpoint inhibitors (ICIs) in im- munotherapies is increasingly common, especially in monotherapy and combination therapy. Recent discoveries have shown that a high tumor muta- tion burden (TMB) correlates with response to ICIs and is emerging as a key biomarker for predicting patient response. Here we present the evalua- tion of the OncomineTM Tumor Mutation Load assay for TMB analysis using FFPE samples. Data shown will include correlation with TMB measured by exome sequencing and microsatellite instability (MSI) status.

12:15 PM - 1:00 PM
Advancing Oncology Biomarker Discovery Through Latest innovations in NGS

  • Clarence Lee, Ph.D – Sr. Manager NGS Scientific Content & Collaborations, Thermo Fisher Scientific, Waltham MA

Advances in targeted next-generation sequencing (NGS) have been instrumental in quickening the pace of discovery in oncology and translational research. Discoveries such as T cell receptor (TCR) clonality that can further augment immune therapy success is made possible by enabling researchers to sequence genes of interest in rapid, cost effective manner. This presentation will highlight TCR clonality and other discoveries made possible by TCR sequencing using our latest AmpliSeqTM immuno-oncology assays. The latest innovations in library amplification technolo- gy for Ion TorrentTM will also be discussed, giving you the power to discover low-frequency alleles in circulating tumor DNA with confidence.